Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Lancet Oncol
; 19(4): 497-509, 2018 04.
Article
in En
| MEDLINE
| ID: mdl-29501363
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Triple Negative Breast Neoplasms
Type of study:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2018
Type:
Article